latest consensu today
look clariti growth deliveri
first take earn
ortho market vs cse due ou knee us
expect solid overhang like overshadow quarter
 way train continu pick-up
follow-up ep in-lin sale us knee improv guidanc
lower disappoint guid
infrastructur action alberta ponder power pipelin pursuit
med-tech recap preview
week earn smid-cap face tough act follow strong result
lc
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price month
latest consensu today
advanc neurocrin report result monday close
et assess latest consensu estim today
dial-in detail us confer id
elagolix royalti report sale estim
royalti neurocrin slightli expect
date product utc date dissemin utc
look clariti growth deliveri
expect molson coor report ep yoy vs consensu poor spring
weather market invest peak sell season possibl weigh top bottom
line off-set mainstream share gain taken abi base convers investor
bull optic see posit miller perform new dividend floor suggest
near-term risk/reward earn skew posit even question sustain deliveri
fundament improv maintain under-perform rate molson coor report bmo
earli sign posit obstacl remain juli retail scanner data appear posit key
millercoor brand particularli miller strongest growth
mainstream-light categori fmb strong holiday period line outsiz
categori growth hard seltzers/rtd mix drink erp roll-out albani breweri time
invest tough comp still keep us cautiou expect rev
ep yoy
run fall behind overexposur declin mainstream brand revenue
declin annual remain hurdl high-end brand rel small yet
grow line broader industri believ late bold move need
structur shift portfolio particularli given debt level ltm net debt/ebitda although
rais dividend may support share initi detail
estim valuat adjust ep estim prior street
due sign sequenti better us volum model rais dividend div
per share/yield target price goe base price-to-earnings
ebitda out-year estimate discount upsid risk
date product utc date dissemin utc
price month
price month
slight increas capital-expenditure budget rais full year capital-expenditure guidanc
reflect increment activ associ recent acreag extens
extend later footag exist pad increment four net well ad
drill program due effici gain faster drill time magnitud
hike trivial easili fund within cash flow optic odd broader
sector narr look particularli offsid consid associ cut growth
mention increas later length delay product contribut pad
prompt cut product growth guidanc prior initi
rang guidanc mmcfed consensus/cs
importantli provid disappoint initi guidanc capital-expenditure
modestli expect yoy growth well consensu
prior cse impli weaker capit effici vs expect updat lower capex/
volum littl chang current strip price lower
cfp cut
cfps/ebitdx beat product line clean cfp beat consensus/cs
ebitdx yoy expect volum
mmcfed yoy came top-end guidanc line expect
realiz improv yoy tighter diff cost fell yoy
better cse capital-expenditure consensus/cs still
enabl organ surplu post-divi expect repurchas
share increas buy-back author share author
expens vs peer tp base ebitdx
date product utc date dissemin utc
first take earn
compstore ep in-lin adj ep in-lin sell-sid consensu
us compstore out-performance focu today compstore acceler
consensu driven nation local valu includ mix match deal
posit contribut experi futur eotf remodel strength core
menu intern oper market iom compstore increas consensu
reflect strength uk franc germani posit result across market
intern development licens market compstore increas consensu
strong sale across geograph region
primari driver compstore signific us out-performance quarter
detail share regard deliveri includ sale contribut recent chang
term eat expect roll-out doordash sale initi
expect impact drive on-going share gain expect time
roll digit menu board us store technolog
perform updat regard evolut valu strategi expect
remaind year us breakfast busi perform drive
increas food cost intern market expect increas
prior market drive upsid net restaur growth net addit vs prior
composit compstore traffic/ticket
link preview sale assembl earn preview
date product utc date dissemin utc
price month
happen psxp report adj ebitda beat cse
street consensu adj dcf beat cse stronger
expect equiti earn drove beat potenti due better expect bayou bridg
contribut volum explor dapl
what import psxp announc elimin idr psx gener partner
interest exchang psxp common unit equiti valu base close
price multipl base yesterday close within
rang expect skew toward higher end time also slightli sooner
expect expect later manag guid accret
chang asid idr elimin psxp announc clemen gregori
pipelin ethan pipelin expect connect clemen cavern
petrochem facil near corpu christi project expect complet
back long-term contract like relat xom-sab cracker gray oak
remain on-track enter servic end south texa gateway also remain on-track
start-up announc frac sweeney isd
stock react expect slight neg reaction idr elimin partial
off-set result beat market never anticip backdoor cut see sigh
relief boost perform today near-term dilut could weigh sentiment
expect call focu accret expect move forward without idr
date product utc date dissemin utc
price month
expect solid overhang like
overshadow quarter
bottom line believ teva could report better-than-curr sell-sid forecast top
bottom line compani releas result august maintain
revenu estimate vs consensu rais ep vs
consensu driven larg chang product mix higher copaxon sale
along higher gross margin howev potenti liabil opioid/drug price litig
remain key overhang name
notabl model updat increas global sale estim copaxon
vs con austedo vs con lower ajovi
vs con howev think street unlik give teva credit higher
copaxon sale gener side lower north america gener revenu estimate
vs con rais eu gener busi modestli vs
con maintain intern gener revenu vs con
rais ep maintain ep
respect
earn look commentari opioid multi-district litig
on-going gener drug price-fix litig updat commerci uptak key growth
driver ajovi austedo better visibl new gener launch includ forteo
nuvar gener price environ copaxon competit landscap
maintain neutral rate lower target price maintain neutral rate
lower target price ev/ebitda ev/ebitda given
increas concern potenti ajovi under-perform due recent slowdown
cgrp migrain class along lack visibl potenti liabil opioid
gener price fix litig risk includ better/worse-than-expect liabil opioid/
price fix issu sale branded/gener busi particular uptak
ajovi austedo
date product utc date dissemin utc
 way train continu pick-up
pace ahead lt target ehth strong result increas outlook
mean compani pace ahead long-term target howev remain focus
deliv expect evalu rel invest etc
formal look lt outlook issu coupl month back
ltv trend strong guidanc assum moder ehth ltv grew y/i
driven higher reimburs rate fav product mix better retent
member cohort seen signific chang retent rate
older cohort member compani observ higher averag churn among
member enrol like driven oep result expect
ltv declin mid-singl digit rang reflect similar phenomenon occur next
put take expect total revenue seq declin driven seq
declin ifp given roughli mln tail revenue recogn medicar revenue expect
essenti flat sequenti addit expect sequenti acceler
invest includ addit telesal agent invest
expect improv posit drag ebitda overal expect
ebitda three-fold loss compar impli ebitda loss mln
rais estim pt reiter outperform rais revenu
ebitda estim strong momentum busi slightli rais ev/
revenu multipl revenu estim yield pt
prev risk pt rate includ compani invest yield
desir result slowdown medicar market
date product utc date dissemin utc
follow-up ep in-lin sale us
knee improv guidanc rais
upsid cc growth vs cse consensu sale bil
mil higher estim consensu bil rel estim
knee spine partial off-set lower set
us knee vs cse includ contribut robot system
ep vs consensu cse sale net cog partial off-set
higher deliv beat ep rel estim consensu gm
bp better cs estim
cc guidanc increas cc sale guidanc
bottom-end ep rais
date product utc date dissemin utc
price month
lower disappoint
slow growth/capex strategi reduc gener modestli dilut
valuat revis guidanc didnt help think main driver behind today
share price under-perform cog disappoint outlook yoy growth
budget vs consensu yoy similar capital-expenditure slower growth/capex
strategi effort maxim lower ga price also suggest lose
operational/logist effici move larger pad oper much larger product
base weve lower volum compound-annual-growth-rate reduc cog
estim cumul surplu assum strip price leav trade
expens ev/ebitdx earlier today lower cfp cut
forecast
increas budget lower growth guidanc rais capital-expenditure budget
extend later footag larg pad ad increment
well program due faster drill time rel neglig increas
nonetheless odd heighten investor scrutini spend meanwhil cut growth
guidanc cycl time associ longer later push
product contribut pad project guidanc mmcfed
expect
price month
print modestli better expect clean cfp beat consensus/cs
ebitdx yoy expect volum
mmcfed yoy top-end guidanc line expect capital-expenditure
consensus/cs still enabl surplu
post-dividend repurchas share increas buy-back author
expens vs peer tp base normal ev/ebitdx
risk ga prices/differenti execut
date product utc date dissemin utc
infrastructur action alberta
ponder power pipelin pursuit
thought focu two key issu alberta centric chang path
alberta power market capac orient futur energi market plenti
pipelin pronounc call result season creat addit volatil name like
enbridg inc enb firstli alberta govern move power market energi
framework roughli year systemat progress toward capac market near-
term believ chang meaning major power produc capit power
transalta howev clear challeng shift energi market
long-term basi larg behaviour unintend consequ like manifest
futur issu secondli sever energi result call outlin rail
among issu larg part convers arguabl statement like
cenovu cve help neg sentiment toward enb intra-day basi
cve confer call
regard line think end obvious highli optimist
think delay time
date product utc date dissemin utc
med-tech recap preview
follow strong result lc
earn op potenti meet exceed expect cse
mil sale cc organ ep topic includ ou trend vs priori
year comp us spine puls robot surgeri launch margin trend
earn op expect meet beat sale ep
estim cse mil sale cc organ ep topic includ
robot surgeri system trend spine growth improv ebitda margin fx impact
ew signific us ww tavr drive ep upsid us tavr grew upper teen
ou tavr grew mid-teen ep estim management rais guidanc
guid ensur street get ahead reiter outperform
deliv org growth guidanc rais management deliv impress quarter
boost strong growth across portfolio core busi line robot
estim guidanc rais
ortho round-up pace gain continu loss slow analysi
indic ww ortho market grow bp faster expect due primarili ou
knee cc vs cse us hip vs cse gain share
us knee mostli zbh share loss slow quarter
ytd bp bp ms ltm vs
ms led group week
perform ew lead ytd lc ms ntm ev/
ebitda vs vs last week respect
date product utc date dissemin utc
 visa particip seri fund go-jek ride-shar mobil wallet provid
south east asia goal acceler mobil payment across southeast asia fast-
grow region take could also land grab promot visa-credenti
payment similar paypal invest long ago pymnt com
 announc acquir paywork cloud-bas provid payment gateway po
previous particip paywork mil fund round back februari well
plan combin paywork cloud-bas solut in-stor payment process
cybersourc digit payment management platform creat integr accept solut
merchant acquir take materi financi impact note
 activ year bolster capabl acquisit strateg
releas newest edit global destin citi report detail top
market global travel take disclosur clear inbound commerc
